List of Quillichew Er drug patents
Quillichew Er is owned by Nextwave Pharms.
Quillichew Er contains Methylphenidate Hydrochloride.
Quillichew Er has a total of 9 drug patents out of which 0 drug patents have expired.
Quillichew Er was authorised for market use on 04 December, 2015.
Quillichew Er is available in tablet, extended release, chewable;oral dosage forms.
Quillichew Er can be used as a method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed, a method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed, a method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1.
The generics of Quillichew Er are possible to be released after 14 August, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8202537 | NEXTWAVE PHARMS | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8287903 | NEXTWAVE PHARMS | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(8 years from now) | |
| US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic